• Welcome
  • The Board
  • Our Investors
  • soloMER Technology
  • Licensing Opportunities
  • Pipeline
  • Publications
  • Contact
  • News
ELASMOGEN
Elasmogen presenting latest SDC data at Antibody Engineering & Therapeutics in Basel, June 10-12th 2025

Elasmogen presenting latest SDC data at Antibody Engineering & Therapeutics in Basel, June 10-12th 2025

by Lorna Bowers | May 14, 2025 | News

Euan Murray (Senior Scientist) will attend Antibody Engineering & Therapeutics in Basel, June 10-12th 2025, and present a talk titled First-in-class Site-directed Targeted soloMER Drug Conjugate for Autoimmune Inflammation.  He will describe the synthesis and...
Elasmogen presenting latest data at PEGS Summit in Boston, 12-16th May 2025

Elasmogen presenting latest data at PEGS Summit in Boston, 12-16th May 2025

by Lorna Bowers | May 5, 2025 | News

Stella Priyanka (Senior Scientist) will be presenting the latest data on our first-in-class soloMER drug conjugate, ELN28, at PEGS Boston Summit, May 2025. Her poster, “Characterization of a Bi-Functional soloMER® Drug Conjugate (SDC) Targeting TNFα and JAK...

News archives

  • May 2025
  • March 2025
  • December 2024
  • June 2024
  • April 2024
  • November 2023
  • June 2023
  • May 2023
  • April 2023
  • December 2022
  • September 2022
  • May 2022
  • December 2021
  • September 2021
  • January 2021
  • December 2020
  • July 2020
  • May 2020
  • April 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • July 2019
  • May 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • May 2018
  • January 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • August 2016
  • July 2016
  • March 2016
  • December 2015
  • Follow
welcome
the board
our investors
soloMER® technology
licensing opportunities
pipeline
publications
contact
news

Liberty Building
Foresterhill Health Campus
Foresterhill Rd
Aberdeen AB25 2ZP

t: (+44) 070 7721 0755